The Management Board
Michael Milane, MD, MBA, MPH
PRESIDENT & CEO
With 12 years of Pharmaceutical industry experience in Clinical Development and Medical Affairs, Dr. Milane has served as a physician executive in multiple Pharma companies (previous CMO).
With a clinical and research training background from UCLA & NIH, he has developed high level scientific programs, clinical trials, FDA assets and educational resources in Dermatology.
His MBA training and executive experience have provided for strong corporate strategy in business development, startups, capital raise & a NASDAQ IPO.
Daniel Siegel, MD, MS
CSO & CHAIR, SCIENTIFIC ADVISORY BOARD
Dr. Siegel is a Clinical Professor of Dermatology at SUNY in NY. He is a former President and honorary member of the American Academy of Dermatology (AAD).
With extensive clinical research experience, he has published over 150 articles and book chapters.
His expertise extends to plant medicines topics and cannabinoid science with a focus on natural medicines. He is often invited to speak on these topics at national & international level conferences.
Michael Burns, PhD
PHARMA & MANUFACTURING ADVISOR
With extensive Executive Pharma experience, Dr. Burns has served as the Chief Operating Officer and President of Ferndale Laboratories Inc.
Experiences span the spectrum of product classes (cosmetics,
nutraceuticals, OTC-drugs, medical devices and Rx), including work in the fields of skin care, analgesia (oxycontin), GI, and oncology.
He brings years of experience in growing a Pharma company and
all the associated departments, such as manufacturing, sales and marketing.
Dan Piacquadio, MD
CLINICAL DEVELOPMENT & FDA ADVISOR
Dr. Piacquadio is the Founder and CEO of Therapeutics Inc. and serves as its President and Chief Executive Officer of the CRO.
He started Therapeutics Inc. as a development business dedicated to the field of dermatology, serving the needs of biotechnology, pharmaceutical, and investment communities.
He carries extensive clinical and drug development expertise and works closely with multiple companies on all stages, including trials and submissions to the FDA
CFO & FINANCIAL ADVISOR
Mr. McDonald is the head of Life Sciences Investment Banking at Lake Street Capital Markets, LLC. With extensive industry and capital markets experience, he most recently served as a senior financial and business development executive for SillaJen Biotherapeutics, Delcath Systems and AngioDynamics where he raised almost $200 million in capital and successfully negotiated a number of global partnerships and acquisitions.
In addition, he has more than 25 years of capital markets experience serving the needs of emerging growth companies as a healthcare investment banker, equity research analyst and investor with RBC Capital Markets, Craig-Hallum, Canaccord Genuity and American Express.
He received his BA in Economics from St. Olaf College. With previous experiences including Chief Business Officer, President at SillaJen, Executive Vice President Business Development, CFO at Delcath Systems, Inc.
He has extensive experience in business development, corporate governance, corporate finance and all components of the IPO process.
The Scientific Advisory Board
Brian Berman, MD, PhD
DERM, AAD LEADERSHIP, CLINICAL TRIALS, FDA, IMMUNOLOGY, KOL SPEAKER
Dr. Berman is Professor Emeritus of Dermatology and Dermatologic Surgery at The University of Miami Miller School of Medicine and is Co-Director of the Center for Clinical and Cosmetic Research.
He has had the honor of serving as a member of the Board of Directors and immediate past Vice President of the AAD and is President-elect of the American Dermatological Association .
With extensive clinical research and immunology experience, he’s a high level national and international speaker on multiple therapeutic topics
Neal Bhatia, MD
DERM, AAD LEADERSHIP, CLINICAL TRIALS (CRO), FDA, IMMUNOLOGY, KOL SPEAKER
Dr. Neal Bhatia is Associate Clinical Professor at Harbor UCLA Medical Center. With extensive research experience, he serves as Director of Clinical Dermatology at Therapeutics Clinical Research Center (CRO).
He is the VP-elect of the AAD and the chief medical editor for Practical Dermatology.
As a world class speaker, he has a strong background in immunology, with interests in mechanisms of therapy for cannabinoids, skin cancer, and medical dermatology.
Clay Cockerell, MD, MBA
DERM PATH, AAD LEADERSHIP, CLINICAL TRIALS, KOL SPEAKER, BUSINESS DEVELOPMENT, ENTREPRENEUR
Dr. Cockerell is a Clinical Professor of Dermatology and Pathology at the University of Texas Southwestern Medical Center and Director of the Division of Dermatopathology .
He is the President and owner of Cockerell Dermatopathology as well as a former president of the American Academy of Dermatology and American Board of Dermatopathology .
With extensive research experience, he’s also a world class speaker. With previous MBA training, he’s a serial entrepreneur with a strong business network and multiple companies developed.
Adam Friedman, MD, FAAD
DERM, NANO TECHNOLOGY, CLINICAL TRIALS, FDA, CRO, KOL SPEAKER, COMPANY & BUSINESS
Dr. Friedman is a board Certified Dermatologist, Professor & Interim Chair of Dermatology Residency Program, Director of Translational Research & Director of Supportive Oncodermatology at the Department of Dermatology of George Washington School of Medicine and Health Sciences.
With multiple publications on the potential role of Cannabinoids in Dermatology, he has a keen interest in more clinical research and translational therapeutics in this space.
Stuart Marcus, MD, PhD
ONCOLOGY, CMO, CLINICAL TRIALS, FDA, CRO, REGULATORY COMPLIANCE, ENTREPRENEUR
With over 25 years of Pharma Clinical development experience, Dr. Marcus has a long and successful FDA track record in the commercial clinical development of therapeutic pharmaceuticals.
His expertise will be used to evaluate and guide the clinical development projects for Greenway’s Rx projects. These will include Phase 1a & b, 2a & 3 studies in multiple indications with the FDA. He will also provide for strong regulatory and compliance components at all levels for the company’s development.
Todd Schlesinger, MD, FAAD
DERM, COSMECEUTICALS, CLINICAL TRIALS, FDA, CRO, KOL SPEAKER, COMPANY & BUSINESS
Dr. Schlesinger is a Board Certified Dermatologist, Dermatologic surgeon, and Cosmetic Dermatologist.
He founded the Clinical Research Center of the Carolinas where he is currently conducting over 35 clinical trials of new therapies and
Additionally, he is a national trainer, global speaker, and consultant to numerous pharmaceutical, cosmetic, and technology companies. He has a strong business development acumen, corporate network, and resources.